March 25, 2008--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that Tom Megerian, M.D., Ph.D, executive director, clinical research of EPIX, is scheduled to present an oral presentation entitled "Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer's Disease" at the Keystone Symposia Alzheimer's Disease Meeting in Keystone, Colorado on Friday, March 28, 2008 at 8:00 a.m. MDT. EPIX previously announced the compelling results of a Phase 2a clinical trial of PRX-03140 as a single agent and in combination with Aricept(R) in patients with mild Alzheimer's disease. Dr. Megerian's presentation will focus on these previously reported data.
PRX-03140 is part of EPIX's strategic partnership with GlaxoSmithKline... EPIX's Press Release -
